HA35 Moderate Alcoholic Hepatitis (AH) Study
Mechanism of HA35 in Patients With Alcoholic Liver Disease
The Cleveland Clinic
54 participants
Sep 1, 2022
INTERVENTIONAL
Conditions
Summary
Eligible participants will be asked to take a placebo/treatment capsule for 90 days and participate in two in-person study visits, one at the start of the 90 days and the second at the completion of study supplement administration. Both visits will include a physical exam, clinical labs, body composition measurements, muscle strength tests, questionnaires, and urine and stool collections. Additionally, a sugar cocktail will be consumed to measure gut permeability and a muscle biopsy will be collected. The day after the visits, you will need to return to drop off the 24-hour urine collection. Two phone visits will be performed in between the in-person visits at day 30 and 60 where you will be asked a series of questionnaires as well as asked about study supplement compliance.
Eligibility
Inclusion Criteria7
- Clinical diagnosis of alcoholic hepatitis defined as:
- Regular consumption of alcohol with an intake of >60 g daily or >420 g weekly on average for men and >40 g daily or >280 g weekly on average for women for 6 months or more
- AND
- MELD <21
- Serum total bilirubin >3 mg/dL
- AST >50 IU/I; AST:ALT ratio >1.5; Both AST and ALT <400 IU/I
- OR Histologic evidence of AH.
Exclusion Criteria19
- Pregnant or breastfeeding women
- Patients with gastrointestinal bleeding within 2 weeks
- Active infection (positive blood or ascitic fluid culture)
- Overt encephalopathy
- Renal failure and/or on dialysis
- Medications that alter muscle protein metabolism
- Myopathies
- Other end-stage organ diseases
- Malignancy
- Solid organ or hematopoietic transplantation
- Active alcohol withdrawal or ongoing participation in a Clinical Institute Withdrawal Assessment (CIWA) protocol
- History of recent upper gastrointestinal resection within past 6 months
- Acute or chronic liver disease due to other active causes, in addition to alcoholic liver disease
- Inability to provide consent
- Creatinine >2mg/dL
- Platelets <60,000k/ul
- PT/INR >1.7
- Presence of pedal edema
- Use of anti-platelet/anticoagulation drugs or medications that interfere with blood clotting
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Sodium hyaluronate of molecular weight 35kDa will be given in capsule form to study participants
A placebo will be given in capsule form to study participants
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05018481